![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsors and Collaborators: |
King Faisal Specialist Hospital & Research Center Novartis |
---|---|
Information provided by: | King Faisal Specialist Hospital & Research Center |
ClinicalTrials.gov Identifier: | NCT00532649 |
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients with Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
Condition | Intervention |
---|---|
Chronic Myeloid Leukemia |
Drug: AMN 107 (Nilotinib) |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment |
Genders Eligible for Study: | Both |
Inclusion Criteria: - Patients with Imatinib resistant CML in blast crisis
Contact: Naeem A Chaudhri, MD | 966-1-4647272 ext 32019 | chaudhri@kfshrc.edu.sa |
Saudi Arabia | |
KFSH&RC | Recruiting |
Riyadh, Saudi Arabia, 1211 | |
Contact: Naeem A Chaudhri, MD 966-1-4647272 ext 32019 chaudhri@kfshrc.edu.sa |
Principal Investigator: | Naeem Chaudhri, MD | King Faisal Specialist Hospital & Research Center, Riyadh |
Principal Investigator: | Naeem A Chaudhri, MD | KFSH&RC |
Study ID Numbers: | CAMN107A2109 |
Study First Received: | September 17, 2007 |
Last Updated: | September 19, 2007 |
ClinicalTrials.gov Identifier: | NCT00532649 History of Changes |
Health Authority: | United States: Food and Drug Administration |
CML |
Imatinib Blast Crisis Leukemia Hematologic Diseases Myeloproliferative Disorders |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Chronic Myelogenous Leukemia Leukemia, Myeloid Bone Marrow Diseases |
Leukemia Neoplasms Neoplasms by Histologic Type Hematologic Diseases |
Myeloproliferative Disorders Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myeloid Bone Marrow Diseases |